rhDNAse (Dornase alfa) and Its Role in the Management of COVID-19

Öz

Neutrophil leukocytes (NL) are the fastest-reacting cells on the front line struggling against pathogenic microorganisms in the body. Swift response by the NLs in the patients with COVID-19 is useful for the body, although the untoward, inadvertently proceeding in this response is thought to enhance life-threatening pulmonary damage and pave the way to death of the patient. The phenomenon known as ‘cytokine storm’ is a general term describing this unwanted reaction by the body and is the result of complicated intriguing cellular and biochemical processes.

So-called “neutrophil extracellular traps” (NETs) trigger progressing to ARDS and respiratory failure in critical cases with COVID-19. rhDNAse (Dornase alfa) is an agent postulated to hydrolyze DNA networks released by the killed NLs and thus reverse the deadly process in the lungs. Its major drawbacks are cost and inability to apply to mild-to-moderate cases in order to prevent deterioration to a critical illness. Nonetheless, it can represent a promising new therapeutic modality in the future. 

Anahtar Kelimeler

• rhDNAse
• COVID-19
• Dornase alfa
• Treatment

rhDNAz (Dornase alfa) Nedir, COVID-19 Tedavisinde Yeri Var mıdır?

Öz

Nötrofil lökositler (NL) vücutta hastalık yapan mikroorganizmalarla savaşın en ön cephesindeki hücrelerdir ve hemen yanıt verirler. COVID-19 olgularında da NL’lerin hızla yanıt vermesi olumlu, iyileştirici bir faktördür; fakat bu yanıtın istenmeyen aşırı bir noktaya gelmesinin akciğer hasarını artırdığı ve ölüme giden yolu tetiklediği düşünülmektedir. ‘Sitokin fırtınası’ kavramı bu abartılı yanıtın genel adıdır ve birçok hücresel ve biyokimyasal yanıtın ilişkilerinin sonucudur. Akciğerde “neutrophil extracellular traps” (NETs) oluşumu COVID-19 enfeksiyonunun ARDS’ye ve solunum yetmezliğine ilerlemesinin belirleyici sürecidir. rhDNAz (Dornase alfa) burada lökositlerden açığa çıkan DNA’ları parçalayarak süreci geriye çevirebilmektedir. Pahalılığı ve orta şiddetteki hastalarda uygulanamaması şu an çekinceleri oluştursa da gelecek için ümit veren bir tedavi modalitesi olabilir.

Anahtar Kelimeler

• rhDNAz
• Dornaz Alfa
• Kovid-19
• Tedavi

Kaynakça

1. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps J Exp Med. (2020) 217 (6): e20200652
2. Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans [published online ahead of print, 2020 May 27]. Lancet Respir Med. 2020;S2213-2600(20)30243-5. doi:10.1016/S2213-2600(20)30243-5
3. Yao XH, Li TY, He ZC, et al. [A Pathological Report of Three COVID-19 Cases by Minimal Invasive Autopsies] [Article in Chinese] Zhonghua Bing Li Xue Za Zhi. 2020;49(5):411-417. doi:10.3760/cma.j.cn112151-20200312-00193
4. Papayannopoulos, V., D. Staab, and A. Zychlinsky. 2011. Neutrophil elastase enhances sputum solubilization in cystic fibrosis patients receiving DNase therapy. PLoS One. 2011;6(12):e28526.
5. Erdeve O, Uras N, Atasay B, Arsan S. Efficacy and safety of nebulized recombinant human DNase as rescue treatment for persistent atelectasis in newborns: case-series. Croat Med J. 48 (2),234–9. 2007.
6. Hendriks T, de Hoog M, Lequin MH, Devos AS, Merkus PJ. DNase and atelectasis in non-cystic fibrosis pediatric patients. Crit Care. 9 (4), R351-6. 2005.
7. Fitzgerald DA, Hilton J, Jepson B, Smith L. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics 2005;116(4):e549-54.
8. Çalkavur Ş, Olukman Ö, Ercan G, et al. Practice of Intratracheal and Inhaled Recombinant Human Deoxyribonuclease (rhDNase) Therapy in Neonates with Persistent Atelectasis: A Rescue Treatment. Turkiye Klinikleri J Med Sci. 2013;33(4):1143-50.

9. Livingston MH, Mahant S, Connolly B, et al. Effectiveness of Intrapleural Tissue Plasminogen Activator and Dornase Alfa vs Tissue Plasminogen Activator Alone in Children with Pleural Empyema: A Randomized Clinical Trial. JAMA Pediatr 2020 Feb 3. doi: 10.1001/jamapediatrics.2019.5863. [Epub ahead of print]
10. Lv, X., T. Wen, J. Song, D. Xie, L. Wu, X. Jiang, P. Jiang, and Z. Wen. 2017. Extracellular histones are clinically relevant mediators in the pathogenesis of acute respiratory distress syndrome. Respir. Res. 18:165. https://doi.org/10.1186/s12931-017-0651-5
11. Caudrillier, A., K. Kessenbrock, B.M. Gilliss, J.X. Nguyen, M.B. Marques, M. Monestier, P. Toy, Z. Werb, and M.R. Looney. 2012. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J. Clin. Invest. 122:2661–2671. https://doi.org/10.1172/JCI61303
12. Cortjens B, de Jong R, Bonsing JG, van Woensel JBM, Antonis AFG, Bem RA. Local dornase alfa treatment reduces NETs-induced airway obstruction during severe RSV infection. Thorax 2018 Jun;73(6):578-580. doi: 10.1136/thoraxjnl-2017-210289. Epub 2017 Aug 5.